ClinicalTrialsFinder

CIMCA ( Site 0551)

San José, Provincia de San José, Costa Rica

1 recruiting

Showing 1–1 of 1 trials

Recruiting
Phase 3

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled257 locationsNCT06312176